Friday, 16 October 2026European Markets

VAN DE VELDE And BARBARA BUI Have A High Dividend Yield And Return On Equity In The Apparel Manufacturing Industry.

Loading stream...

(vianews) - van de velde (van.br) is among this list of stock assets with the highest dividend rate and return on equity on the apparel manufacturing industry.

financial asset price forward dividend yield return on equity
van de velde (van.br) €32.55 6.88% 20.14%
barbara bui (bui.pa) €8.70 4.08% 125.51%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. van de velde (van.br)

6.88% forward dividend yield and 20.14% return on equity

van de velde nv, together with its subsidiaries, designs, develops, manufactures, and markets fashionable luxury lingerie and swimwear in europe and north america. the company operates through two segments, business to business and direct to consumer. it offers its products under the primadonna, marie jo, and sarda brand names. the company provides its products through its retail networks, website, and department stores, as well as independent retail and e-tail partners, franchisees, and marketplaces. van de velde nv was founded in 1919 and is headquartered in schellebelle, belgium. van de velde nv is a subsidiary of van de velde holding nv.

earnings per share

as for profitability, van de velde has a trailing twelve months eps of €2.61.

pe ratio

van de velde has a trailing twelve months price to earnings ratio of 12.47. meaning, the purchaser of the share is investing €12.47 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.14%.

volatility

van de velde's last week, last month's, and last quarter's current intraday variation average was a negative 2.52%, a negative 0.34%, and a positive 1.20%.

van de velde's highest amplitude of average volatility was 2.61% (last week), 0.97% (last month), and 1.20% (last quarter).

volume

today's last reported volume for van de velde is 8660 which is 0.39% below its average volume of 8694.

more news about van de velde.

2. barbara bui (bui.pa)

4.08% forward dividend yield and 125.51% return on equity

barbara bui sa engages in the manufacture, marketing, and sale of ready-to-wear clothing and accessories for women in france and internationally. the company offers coats, jackets, tops and shirts, t-shirts, mesh, pants, dresses and skirts, leather products, and tailored cloths; and accessories, such as shoes, bags, scarves, and belts. it offers its products through wholesale distributors, as well as online and offline stores. the company was incorporated in 1982 and is based in paris, france.

earnings per share

as for profitability, barbara bui has a trailing twelve months eps of €1.04.

pe ratio

barbara bui has a trailing twelve months price to earnings ratio of 8.37. meaning, the purchaser of the share is investing €8.37 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 125.51%.

more news about barbara bui.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com